In line with this principle, tigecycline—an antibiotic that inhibits the mitochondrial ribosome and impairs OxPhos activity [13, 14]—showed increased toxicity toward either MYC‐overexpressing cells [11, 12] or DLBCL cell lines of the CCC‐OxPhos subtype [15]. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.